The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Provided herein are methods for identifying new biomarkers for various diseases using proteomics, peptidomics, metabolics, proteoglycomics, glvcomics, mass spectrometry and machine learning. The present disclosure also provides glycopeptides as biomarkers for various diseases such as cancer and autoimmune diseases.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

The disclosure features methods and systems that include directing an ion beam to a region of a sample to liberate charged particles from the region of the sample, where the directed ion beam is pulsed at a first repetition rate, deflecting a first subset of the liberated charged particles from a first path to a second path different from the first path in response to a gate signal synchronized with the repetition rate of the pulsed ion beam, and detecting the first subset of the liberated charged particles in a time-of-flight (TOF) mass spectrometer to determine information about the sample, where the gate signal sets a common reference time for the TOF mass spectrometer for the first subset of charged particles liberated by each pulse of the ion beam.

The present invention relates to a labeled chimeric non-therapeutic antibodylike protein comprising, in a hypervariable region thereof, an enzyme cleavable peptide sequence derived from a hypervariable region of a reference therapeutic antibody.

A system comprises: (a) a robotic arm; (b) a needle capillary coupled to the robotic arm; (c) a cell coupled to the robotic arm comprising: a housing; first and second windows disposed within the housing and defining a width of an internal chamber therebetween; a collimating lens optically coupled to the first window; a focusing lens optically coupled to the second window; an inlet port fluidically coupled to a first end of the internal chamber; and an outlet port fluidically coupled to a second end of the internal chamber; (d) a pump; (e) first and second tubings fluidically coupled, respectively, between the needle capillary and the inlet port and between the pump and the outlet port; (f) a light source; (g) a photodetector; and (h) first and second optical fibers optically coupled, respectively, between the light source and the collimating lens and between the photodetector and the focusing lens.

In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.

The present invention provides rapid, sensitive high-throughput methods and systems for characterizing peptides or proteins using affinity-based chromatography-coupled native mass spectrometry to improve manufacturing process of biopharmaceutical products, such as identifying impurities during antibody purification, monitoring post-translational modification variants during production, or characterizing drug-to-antibody ratio of antibody-drug conjugates. The separation profiles of the peptides or proteins are generated and compared to identify or qualify the peptides or proteins, wherein the separation profile is based on differential affinity binding.

Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.

Described are methods, compositions, and devices for a concatemeric protein standard that behaves as a protein but transforms into single peptides upon digestion, which is optimized to function as a non-obtrusive process control for mass spectrometry analysis.